Skip to content

European and US regulators approve AbbVie's new combo for all hepatitis C genotypes

Demand for access to NHS PrEP trial looks set to outstrip places

Demand for access to NHS PrEP trial looks set to outstrip places

PrEP demand in England is rapidly accelerating – and most will want to join the trial

PrEP demand in England is rapidly accelerating – and most will want to join the trial

What marks out HIV controllers from others?

Michaela Müller-Trutwin at the HIV Cure and Cancer Forum, IAS 2017. Photo by Marcus Rose/IAS

Why curing HIV may be like curing cancer – and may be as difficult

Monsef Benkirane at the HIV Cure and Cancer Forum, IAS 2017. Photo by Marcus Rose/IAS

Can we achieve a complete HIV cure in more patients?

Michael Louella at the HIV Cure and Cancer Forum, IAS 2017. Photo by Marcus Rose/IAS

VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment

Trevor Crowell at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Long-acting NRTI shows promise for HIV treatment and PrEP

Martin Markowitz at IAS 2017. Photo by Steve Forrest/Workers' Photos/IAS

Stillbirth more frequent in women with HIV in UK and Ireland than in general population

Graziella Favarato at IAS 2017. Image credit: Dr Heather Bailey (@DrHeatherBailey)